Acadia Pharmaceuticals Inc.

company

About

Acadia Pharmaceuticals develops and commercializes small molecule drugs for the treatment of central nervous system disorders.

  • 501 - 1000

Details

Last Funding Type
Debt Financing
Last Funding Money Raised
$22M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jul 16, 1993
Number Of Employee
501 - 1000
Operating Status
Active

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company maintains two wholly owned subsidiaries: Acadia Pharmaceuticals AB based in Malmo, Sweden and Acadia Pharmaceuticals A/S based in Denmark. The Company is developing a portfolio consisting of four product candidates, including the compound, pimavanserin, which it is developing for three separate neurological and psychiatric indications in collaboration with Biovail Laboratories International SRL (Biovail), a subsidiary of Biovail Corp. The indications are Parkinson's disease psychosis, which is in Phase III development, adjunctive therapy in schizophrenia, and Alzheimer's disease psychosis, for which it is initiating a Phase II feasibility study.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$42M
Acadia Pharmaceuticals Inc. has raised a total of $42M in funding over 2 rounds. Their latest funding was raised on Feb 7, 2006 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 7, 2006 Post-IPO Equity $20M 1 Detail
Jun 20, 2000 Debt Financing $22M 2 H&Q Healthcare Investors Detail

Investors

Number of Lead Investors
Number of Investors
1
3
Acadia Pharmaceuticals Inc. is funded by 3 investors. H&Q Healthcare Investors and Nomura International are the most recent investors.
Investor Name Lead Investor Funding Round
H&Q Healthcare Investors Yes Debt Financing
Nomura International Post-IPO Equity
Pacific Rim Ventures Debt Financing